BeiGene, Ltd. (ONC)vsQuoin Pharmaceuticals Ltd DRC (QNRX)
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
QNRX
Quoin Pharmaceuticals Ltd DRC
$8.00
-1.96%
HEALTHCARE · Cap: $13.19M
Smart Verdict
WallStSmart Research — data-driven comparison
ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).
ONC
Hold42
out of 100
Grade: D
QNRX
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Intrinsic value data unavailable for QNRX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
No standout strengths identified
Areas to Watch
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bull Case : QNRX
QNRX has a balanced fundamental profile.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Bear Case : QNRX
The primary concerns for QNRX are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ONC profiles as a hypergrowth stock while QNRX is a value play — different risk/reward profiles.
QNRX carries more volatility with a beta of 1.82 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 25/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Quoin Pharmaceuticals Ltd DRC
HEALTHCARE · BIOTECHNOLOGY · USA
Quoin Pharmaceuticals Ltd (QNRX) is a biotechnology firm focused on developing innovative therapeutics for rare diseases and unmet medical needs. Utilizing advanced drug delivery technologies, the company enhances the efficacy and safety of established compounds, solidifying its position within the specialty pharmaceuticals sector. Quoin's robust pipeline includes therapies aimed at critical conditions, paving the way for potential clinical advancements and market opportunities. As the company progresses through its clinical trials, it remains dedicated to fostering value for both patients and shareholders through strategic collaborations and cutting-edge research initiatives.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?